carvedilol has been researched along with natriuretic peptide, brain in 87 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.15) | 18.2507 |
| 2000's | 55 (63.22) | 29.6817 |
| 2010's | 25 (28.74) | 24.3611 |
| 2020's | 6 (6.90) | 2.80 |
| Authors | Studies |
|---|---|
| Doughty, R; Espiner, EA; Frampton, C; Ikram, H; Macmahon, S; Nicholls, MG; Richards, AM; Sharpe, N; Yandle, TG | 1 |
| Fujimura, M; Ishida, Y; Komamura, K; Miyatake, K; Nakatani, S; Yamagishi, M; Yasumura, Y | 1 |
| Aizawa, Y; Fuse, K; Hanawa, H; Hirono, S; Ito, M; Kato, K; Kodama, M; Ma, M; Nakazawa, M; Ohta, Y; Tanabe, T; Watanabe, K; Yamamoto, T | 1 |
| Hata, K; Kawai, H; Kawai, K; Takaoka, H; Yokoyama, M | 1 |
| Doughty, R; Espiner, EA; Frampton, C; MacMahon, S; Murphy, J; Nicholls, MG; Richards, AM; Sharpe, N; Yandle, TG | 1 |
| Hanatani, A; Hirooka, K; Hori, M; Ishida, Y; Komamura, K; Miyatake, K; Nakatani, S; Yamagishi, M; Yasumura, Y | 1 |
| Bellorini, M; Desnos, M; Fulla, Y; Funck, F; Guillard, N; Hagege, A; Jourdain, P; Loiret, J; Thebault, B | 1 |
| Boucek, MM; Burch, GH; Burr, J; Curtin, EL; Hsu, DT; LaSalle, B; Mahony, L; Pahl, E; Schlencker-Herceg, R; Shaddy, RE; Sower, B; Tani, LY | 1 |
| Bellorini, M; Desnos, M; Duboc, D; Funck, F; Guillard, N; Jourdain, P; Loiret, J; Thebault, B | 1 |
| Jiang, WP; Liu, ZH; Shen, B; Song, JP | 1 |
| Androne, AS; Hryniewicz, K; Hudaihed, A; Katz, SD | 1 |
| Chan, S; Fung, JW; Nicholls, MG; Richards, AM; Sanderson, JE; Yandle, TG; Yip, G; Yu, CM | 1 |
| Konishi, H; Minouchi, T; Nishio, S; Tsutamoto, T; Yamaji, A | 1 |
| Amann-Zalan, I; Castaigne, A; Coats, AJ; Fowler, MB; Hartmann, F; Hoersch, S; Katus, HA; Krum, H; Mohacsi, P; Packer, M; Rouleau, JL; Tendera, M; Trawinski, J | 1 |
| Friesewinkel, O; Furrer, M; Hänggi, G; Rutschmann, A | 1 |
| Abdulla, J; Køber, L; Torp-Pedersen, C | 1 |
| Baba, A; Iwanaga, S; Mitamura, H; Moritani, K; Nakamura, I; Ogawa, S; Satoh, T; Suzuki, M; Yoshikawa, T; Yoshizawa, A | 1 |
| Fukutomi, T; Itoh, M; Kondo, H; Ogata, M; Shigeyama, J; Sugiura, M; Suzuki, S; Takeda, Y; Yamamoto, K | 1 |
| Amann-Zalan, I; Anker, SD; Castaigne, A; Coats, AJ; Fowler, MB; Hartmann, F; Hoersch, S; Katus, HA; Krum, H; Mohacsi, P; Packer, M; Rouleau, JL; Tendera, M | 1 |
| Candy, G; Essop, R; Kachope, J; Kone, N; Libhaber, C; Norton, GR; Sareli, P; Sliwa, K; Woodiwiss, AJ | 1 |
| Leier, CV | 1 |
| Bellorini, M; Desnos, M; El Hallak, A; Funck, F; Guillard, N; Hery, E; Jourdain, P; Loiret, J; Thebault, B | 1 |
| Chang, H; Kuan, P; Lu, MJ; Shyu, KG; Sun, HY; Wang, BW | 1 |
| Backes, RJ; Bailey, KR; Burnett, JC; Frantz, RP; Grill, D; Hanna, RD; Heublein, D; Mookadam, F; Moualla, SK; Nelson, SM; Nobrega, TP; Olson, LJ | 1 |
| Finsterer, S; Nentwich, Ch; Silber, S | 1 |
| Horie, M; Masuda, D; Matsumoto, T; Matsuo, S; Nakae, I | 1 |
| Bian, WY; Duan, B; Jia, X; Li, W; Li, YS; Wang, F; Wang, L; Xu, ZM | 1 |
| Anzai, T; Kohno, T; Nakamura, I; Ogawa, S; Satoh, T; Yoshikawa, T; Yoshizawa, A | 1 |
| Gao, LJ; Lin, XY; Xiao, LZ; Zhang, HF | 1 |
| Endo, Y; Kasanuki, H; Kawashiro, N; Matsuda, N; Uchida, Y | 1 |
| Gilbert, EM; Greenberg, BH; McCollum, D; Mehra, M; Ordronneau, P; Teerlink, JR | 1 |
| Acikel, M; Arslan, S; Atesal, S; Bozkurt, E; Erol, MK; Gundogdu, F; Senocak, H | 1 |
| Arslan, S; Bozkurt, E; Gundogdu, F; Gurlertop, Y; Karakelleoglu, S; Kiziltunc, A; Senocak, H; Sevimli, S | 1 |
| Mori, K; Oe, K; Yamagata, T | 1 |
| Hatori, T; Ichikawa, S; Kasama, S; Kumakura, H; Kurabayashi, M; Sumino, H; Suzuki, T; Takayama, Y; Toyama, T | 1 |
| Dohi, Y; Kimura, G; Kojima, M; Sato, K; Ueda, R | 1 |
| Yoshikawa, T | 1 |
| Anzai, T; Kohno, T; Meguro, T; Nagatomo, Y; Ogawa, S; Satoh, T; Yoshikawa, T; Yoshizawa, A | 1 |
| Cleland, JG; Komajda, M; Metra, M; Olsson, LG; Poole-Wilson, P; Remme, WJ; Scherhag, A; Spark, PA; Swedberg, K; Torp-Pedersen, C | 1 |
| Hua, C; Hua, L; Huang, J; Huang, Y; Jiang, W; Li, F; Li, N; Li, Y; Wang, F; Wu, Y; Xu, Z | 1 |
| Blume, ED; Boucek, MM; Boucek, RJ; Burr, J; Canter, CE; Dodd, DA; Holubkov, R; Hsu, DT; LaSalle, B; Lukas, MA; Mahony, L; Pahl, E; Rosenthal, DN; Ross, RD; Shaddy, RE; Tani, LY | 1 |
| Anzai, T; Kataoka, M; Kohno, T; Nakamura, I; Ogawa, S; Satoh, T; Yoshikawa, T; Yoshizawa, A | 1 |
| Gustafsson, F; Hildebrandt, PR; Remme, WJ; Riegger, GA; Rosenberg, J | 1 |
| Gackowski, A; Kitliński, M; Nessler, B; Nessler, J; Piwowarska, W; Stepniewski, M | 1 |
| de Boer, RA; van Veldhuisen, DJ | 1 |
| Aronson, JK | 1 |
| Funatsu, T; Hanatani, A; Hashimoto, S; Kato, T; Kitakaze, M; Kitamura, S; Kobayashi, J; Komamura, K; Mano, A; Nakajima, H; Nakatani, T; Niwaya, K; Oda, N; Tagusari, O; Ueda, IH; Yagihara, T | 1 |
| Kitliński, M; Nessler, B; Nessler, J; Piwowarska, W; Stepniewski, M | 1 |
| Bai, YH; Li, R; Li, XL; Liu, XY; Mi, Q; Qian, YR; Yi, QJ; Zhong, JR | 1 |
| Kadota, J; Kawano, Y; Tamura, A | 1 |
| Anzai, T; Baba, A; Kohno, T; Meguro, T; Nagatomo, Y; Ogawa, S; Satoh, T; Yoshikawa, T; Yoshizawa, A | 1 |
| Fujii, M; Horie, M; Kawahara, C; Nishiyama, K; Tanaka, T; Tsutamoto, T; Yamaji, M; Yamamoto, T | 1 |
| Echigo, S; Fukaya, T; Kobayashi, J; Minami, N; Noritake, K; Nozaki, H; Tsuda, E | 1 |
| An, JD; Feng, S; Liang, F | 1 |
| Ikeda, T; Komeda, M; Marui, A; Muranaka, H; Nishina, T; Tsukashita, M; Wang, J; Yoshikawa, E | 1 |
| Fujii, M; Horie, M; Kawahara, C; Nishiyama, K; Tsutamoto, T; Yamaji, M; Yamamoto, T | 1 |
| Aihara, K; Akaike, M; Fujimura, M; Hashizume, S; Ikeda, Y; Iwase, T; Matsumoto, T; Nishiuchi, T; Sumitomo, Y; Yagi, S; Yasumura, Y; Yoshida, S | 1 |
| Hayashi, T; Hosoda, K; Matsuo, M; Miyazaki, A; Sakaguchi, H; Tsuda, E | 1 |
| Hachiya, H; Haraguchi, G; Hirao, K; Inagaki, H; Isobe, M; Kawabata, M; Kimura, S; Konishi, M | 1 |
| Coleman, CF; Elsik, M; Hayward, CS; Jabbour, A; Keogh, AM; Kotlyar, E; Krum, H; Macdonald, PS; Mellemkjaer, S | 1 |
| Addonizio, LJ; Auerbach, SR; Blume, ED; Hsu, DT; Lamour, JM; Mahony, L; Pahl, E; Richmond, ME; Shaddy, RE | 1 |
| Bernstein, HS; Lowenthal, A; Shah, A | 1 |
| Arsenault, M; Couet, J; Lachance, D; Roussel, E; Zendaoui, A | 1 |
| Hanawa, H; Kobayashi, D; Kuroda, T; Murakami, S; Nakano, M; Narita, I; Oda, M; Wada, Y | 1 |
| Akashi, S; Doi, M; Kobayashi, S; Kunitsugu, I; Matsuzaki, M; Murakami, W; Nao, T; Okamura, T; Okuda, S; Susa, T; Tanaka, T; Ueyama, T; Wada, Y; Yamada, J; Yano, M | 1 |
| Alfieri, AB; Briceno, L; Calori, G; Colombo, B; Corti, A; Fragasso, G; Lattuada, G; Locatelli, M; Maranta, F; Margonato, A; Perseghin, G; Salerno, A; Spoladore, R | 1 |
| Hiramatsu, K; Kobayashi, F; Mori, Y; Nishikawa, Y | 1 |
| Fedorowski, A; Gackowski, A; Golebiowska-Wiatrak, R; Kitlinski, M; Melander, O; Nessler, B; Nessler, J; Palka, I | 1 |
| Abdelnoor, M; Arnesen, H; Enger, S; Gjesdal, K; Pripp, AH; Tveit, A; Ulimoen, SR | 1 |
| Akpek, M; Kaya, EG; Kaya, MG; Lam, YY; Sarli, B; Topsakal, R; Yarlioglues, M | 1 |
| Chew, PG; Cleland, JG; Douglas, H; Jan, A; Jones, J; Khand, AU | 1 |
| Li, DH; Ma, SC; Qiao, LY; Shan, RB; Sun, YP; Wei, CP; Zhang, YF | 1 |
| Fragata, FS; Mansur, AP; Marcondes-Santos, M; Strunz, CM | 1 |
| Abe, T; Iwasa, T; Negishi, J; Noritake, K; Tsuda, E | 1 |
| Imamura, T; Kato, NP; Kinugawa, K; Komuro, I; Nitta, D | 1 |
| Geng, J; Liu, Q; Lu, D; Shan, Q; Wang, K; Wang, S; Zhang, B; Zhang, Q | 1 |
| Hori, M; Kitabatake, A; Nagatomo, Y; Okamoto, H; Yoshikawa, T | 1 |
| Min, S; Xiangyu, G; Yi, R | 1 |
| Badve, SV; Carroll, RP; Darssan, D; Fahim, MA; Haluska, BA; Hawley, CM; Ierino, FL; Isbel, NM; Marshall, MR; Pascoe, EM; Pedagogos, E; Pilmore, HL; Roberts, MA; Snelling, P; Stanton, T; Tan, KS; Tonkin, AM; Vergara, LA | 1 |
| Choi, DJ; Hong, SJ; Hong, SK; Jeon, ES; Kang, SM; Kim, EJ; Kim, JJ; Kim, MA; Kim, SY; Lee, HY; Park, CS; Park, DG; Park, JJ; Shin, JH; Yoo, BS | 2 |
| Kinugawa, S; Komuro, I; Masuyama, T; Momomura, SI; Murohara, T; Saito, Y; Tsutsui, H | 1 |
| Fujimoto, E; Hori, Y; Nakamura, T; Nishikawa, Y | 1 |
| Imamura, T; Kinugawa, K; Tanaka, S; Ueno, H | 1 |
| Atz, AM; BaezHernandez, N; Butts, R; Mahony, L; Reisch, J; Sutcliffe, D | 1 |
| Appunni, S; Blaschke, F; Düngen, HD; Edelmann, F; Lacour, P; Loncar, G; McGranaghan, P; Obradovic, D; Pieske, B; Rubens, M; Salami, J; Saxena, A; Tahirovic, E; Trippel, TD; Veledar, E | 1 |
| Abdelazeem, B; Barham, W; Khor, SY; Osman, AF | 1 |
3 review(s) available for carvedilol and natriuretic peptide, brain
| Article | Year |
|---|---|
Methods of assessing the functional status of patients with left ventricular systolic dysfunction in interventional studies: can brain natriuretic peptide measurement be used as surrogate for the traditional methods?
Topics: Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Carbazoles; Carvedilol; Clinical Trials as Topic; Data Collection; Drug Administration Schedule; Enalapril; Exercise Test; Exercise Tolerance; Health Status; Heart Failure; Humans; Imidazolidines; Meta-Analysis as Topic; Metoprolol; Natriuretic Peptide, Brain; Propanolamines; Quality of Life; Statistics as Topic; Treatment Outcome; Ventricular Dysfunction, Left | 2004 |
[The value of BNP determination in general practice].
Topics: Acute Disease; Antihypertensive Agents; Biomarkers; Carbazoles; Carvedilol; Clinical Trials as Topic; Diagnosis, Differential; Dyspnea; Echocardiography; Family Practice; Heart Failure; Humans; Multicenter Studies as Topic; Natriuretic Peptide, Brain; Nerve Tissue Proteins; Peptide Fragments; Predictive Value of Tests; Prognosis; Propanolamines; Sensitivity and Specificity; Vasodilator Agents | 2004 |
[Application of beta-blockers for clinical practice].
Topics: Adrenergic beta-Antagonists; Biomarkers; Carbazoles; Carvedilol; Chronic Disease; Heart Failure; Humans; Natriuretic Peptide, Brain; Propanolamines; Randomized Controlled Trials as Topic; Stroke Volume; Time Factors | 2007 |
42 trial(s) available for carvedilol and natriuretic peptide, brain
| Article | Year |
|---|---|
Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group.
Topics: Arginine Vasopressin; Atrial Natriuretic Factor; Carbazoles; Carvedilol; Double-Blind Method; Heart Failure; Humans; Multivariate Analysis; Myocardial Ischemia; Natriuretic Peptide, Brain; Neuropeptides; Norepinephrine; Predictive Value of Tests; Prognosis; Propanolamines; Survival Analysis; Vasodilator Agents; Ventricular Dysfunction, Left | 1999 |
Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group.
Topics: Adrenergic beta-Antagonists; Adrenomedullin; Biomarkers; Carbazoles; Carvedilol; Chronic Disease; Heart Failure; Humans; Natriuretic Peptide, Brain; Nerve Tissue Proteins; Peptide Fragments; Peptides; Prognosis; Propanolamines; Risk Factors; Ventricular Dysfunction, Left | 2001 |
Comparative left ventricular functional and neurohumoral effects of chronic treatment with carvedilol versus metoprolol in patients with dilated cardiomyopathy.
Topics: 3-Iodobenzylguanidine; Adrenergic beta-Antagonists; Adult; Atrial Natriuretic Factor; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Chronic Disease; Female; Hemodynamics; Humans; Male; Metoprolol; Middle Aged; Natriuretic Peptide, Brain; Neurotransmitter Agents; Norepinephrine; Propanolamines; Therapeutic Equivalency; Tomography, Emission-Computed, Single-Photon; Ventricular Function, Left | 2001 |
The Pediatric Randomized Carvedilol Trial in Children with Heart Failure: rationale and design.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Age Factors; Carbazoles; Carvedilol; Child; Child, Preschool; Drug Administration Schedule; Female; Heart Failure; Humans; Infant; Infant, Newborn; Male; Natriuretic Peptide, Brain; Placebos; Propanolamines; Prospective Studies; Treatment Outcome; Ventricular Dysfunction; Ventricular Function; Ventricular Remodeling | 2002 |
Comparative effects of carvedilol and metoprolol on regional vascular responses to adrenergic stimuli in normal subjects and patients with chronic heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Atrial Natriuretic Factor; Carbazoles; Carvedilol; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Exercise; Female; Forearm; Heart Failure; Humans; Male; Metoprolol; Middle Aged; Muscle, Skeletal; Natriuretic Peptide, Brain; Norepinephrine; Propanolamines; Prospective Studies; Reference Values; Regional Blood Flow; Vascular Resistance; Vasodilator Agents; Vasomotor System | 2003 |
Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Carbazoles; Carvedilol; Drug Therapy, Combination; Heart Failure; Humans; Metoprolol; Natriuretic Peptide, Brain; Propanolamines; Renin; Ventricular Function, Left | 2003 |
Serum carvedilol concentration and its relation to change in plasma brain natriuretic peptide level in the treatment of heart failure: a preliminary study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Propanolamines; Reproducibility of Results; Treatment Outcome | 2003 |
NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy.
Topics: Aged; Biomarkers; Carbazoles; Cardiovascular Agents; Carvedilol; Double-Blind Method; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Nerve Tissue Proteins; Peptide Fragments; Predictive Value of Tests; Prognosis; Propanolamines; Prospective Studies; Stroke Volume | 2004 |
[Severe heart failure: treatment optimisation and monitoring using plasma NT-proBNP levels--an useful tool in clinical practice].
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Diuretics; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Exercise Test; Heart Failure; Humans; Hypertension; Indapamide; Male; Natriuretic Peptide, Brain; Nerve Tissue Proteins; Peptide Fragments; Perindopril; Propanolamines; Reference Values | 2004 |
Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction.
Topics: Activities of Daily Living; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Cardiac Output, Low; Carvedilol; Digitalis Glycosides; Diuretics; Dose-Response Relationship, Drug; Drug Administration Schedule; Exercise Test; Female; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Propanolamines; Stroke Volume; Treatment Outcome | 2004 |
Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial.
Topics: Adrenergic beta-Antagonists; Aged; Biomarkers; Blood Pressure; Carbazoles; Cardiovascular Agents; Carvedilol; Creatinine; Drug Therapy, Combination; Europe; Female; Heart Failure; Hospitalization; Humans; Life Tables; Male; Middle Aged; Myocardial Ischemia; Natriuretic Peptide, Brain; Nerve Tissue Proteins; Peptide Fragments; Predictive Value of Tests; Prognosis; Propanolamines; Proportional Hazards Models; Prospective Studies; Stroke Volume; Survival Analysis | 2004 |
Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Nerve Tissue Proteins; Peptide Fragments; Propanolamines; Prospective Studies; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2004 |
Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Angiotensin II; Atrial Natriuretic Factor; Biomarkers; Carbazoles; Carvedilol; Endothelin-1; Endothelins; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Propanolamines | 2005 |
[Beneficial neurohormonal profiles of beta-blockades in chronic left heart failure].
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Propanolamines; Sensitivity and Specificity; Ventricular Function, Left | 2005 |
Carvedilol exerts more potent antiadrenergic effect than metoprolol in heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Exercise Test; Female; Heart Failure; Heart Function Tests; Heart Rate; Humans; Male; Metoprolol; Middle Aged; Natriuretic Peptide, Brain; Norepinephrine; Propanolamines | 2005 |
[Effects of carvedilol on neurohormone and magnesium metabolism in patients with chronic heart failure].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aldosterone; Angiotensin II; Carbazoles; Carvedilol; Female; Heart Failure; Humans; Magnesium; Male; Middle Aged; Natriuretic Peptide, Brain; Norepinephrine; Propanolamines | 2005 |
Effect of beta-blocker therapy on left atrial function in patients with heart failure: comparison of metoprolol succinate with carvedilol.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Function, Left; Carbazoles; Carvedilol; Echocardiography, Doppler; Female; Heart Failure; Humans; Male; Metoprolol; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Propanolamines; Severity of Illness Index; Treatment Outcome; Ventricular Function, Left | 2007 |
Evaluation of cardiac sympathetic nerve activity and left ventricular remodelling in patients with dilated cardiomyopathy on the treatment containing carvedilol.
Topics: 3-Iodobenzylguanidine; Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Echocardiography; Female; Heart; Heart Rate; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Propanolamines; Prospective Studies; Radiopharmaceuticals; Stroke Volume; Sympathetic Nervous System; Tomography, Emission-Computed, Single-Photon; Ventricular Remodeling | 2007 |
Carvedilol reduces elevated B-type natriuretic peptide in dialyzed patients without heart failure: cardioprotective effect of the beta-blocker.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Biomarkers; Blood Flow Velocity; Blood Pressure; C-Reactive Protein; Carbazoles; Carvedilol; Female; Heart Failure; Heart Rate; Humans; Interleukin-6; Lipoproteins, LDL; Male; Malondialdehyde; Middle Aged; Natriuretic Peptide, Brain; Propanolamines; Renal Dialysis; Research Design; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2007 |
Effects of beta-blocker therapy on high sensitivity c-reactive protein, oxidative stress, and cardiac function in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Biomarkers; C-Reactive Protein; Carbazoles; Carvedilol; Exercise Tolerance; Female; Heart Failure; Humans; Interleukin-6; Lipid Peroxidation; Male; Metoprolol; Middle Aged; Natriuretic Peptide, Brain; Oxidative Stress; Oxygen Consumption; Propanolamines; Radionuclide Ventriculography; Single-Blind Method | 2007 |
Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Female; Heart Failure; Humans; Male; Metoprolol; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Propanolamines | 2007 |
Does NT-proBNP remain a sensitive biomarker for chronic heart failure after administration of a beta-blocker?
Topics: Adrenergic beta-Antagonists; Biomarkers; Bisoprolol; Carbazoles; Carvedilol; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Predictive Value of Tests; Propanolamines; Sensitivity and Specificity; Severity of Illness Index | 2007 |
Carvedilol for children and adolescents with heart failure: a randomized controlled trial.
Topics: Adolescent; Adrenergic beta-Antagonists; Carbazoles; Cardiac Output, Low; Carvedilol; Child; Child, Preschool; Double-Blind Method; Female; Humans; Infant; Male; Natriuretic Peptide, Brain; Propanolamines; Proportional Hazards Models; Prospective Studies; Systole; Ventricular Dysfunction; Ventricular Remodeling | 2007 |
Comparison of the effects of carvedilol and metoprolol on exercise ventilatory efficiency in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Carbazoles; Carbon Dioxide; Carvedilol; Dose-Response Relationship, Drug; Exercise; Female; Heart Failure; Humans; Male; Metoprolol; Middle Aged; Natriuretic Peptide, Brain; Oxygen Consumption; Prognosis; Propanolamines; Pulmonary Ventilation; Stroke Volume | 2008 |
Effect of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Enalapril; Europe; Female; Heart Failure, Systolic; Hospitalization; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Propanolamines; Proportional Hazards Models; Risk Assessment; Time Factors; Treatment Outcome | 2008 |
Concentration of BNP, endothelin 1, pro-inflammatory cytokines (TNF-alpha, IL-6) and exercise capacity in patients with heart failure treated with carvedilol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Endothelin-1; Exercise; Exercise Test; Female; Heart Failure; Humans; Interleukin-6; Male; Middle Aged; Natriuretic Peptide, Brain; Oxygen Consumption; Propanolamines; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha; Ventricular Dysfunction, Left | 2008 |
[Preliminary study on the effect of carvedilol on children with primary endocardial fibroelastosis].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Child; Child, Preschool; Endocardial Fibroelastosis; Female; Humans; Infant; Male; Natriuretic Peptide, Brain; Propanolamines; Treatment Outcome | 2008 |
Carvedilol reduces the severity of central sleep apnea in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Dose-Response Relationship, Drug; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Polysomnography; Propanolamines; Prospective Studies; Severity of Illness Index; Sleep Apnea, Central; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left | 2009 |
A pilot study on the role of autoantibody targeting the beta1-adrenergic receptor in the response to beta-blocker therapy for congestive heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Autoantibodies; Carbazoles; Carvedilol; Diastole; Enzyme-Linked Immunosorbent Assay; Female; Heart Failure; Heart Rate; Heart Ventricles; Humans; Male; Metoprolol; Middle Aged; Natriuretic Peptide, Brain; Norepinephrine; Pilot Projects; Propanolamines; Radiography; Receptors, Adrenergic, beta-1; Stroke Volume; Systole | 2009 |
Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Cross-Over Studies; Echocardiography; Female; Heart Failure; Humans; Male; Metoprolol; Middle Aged; Natriuretic Peptide, Brain; Propanolamines; Pulmonary Disease, Chronic Obstructive; Pulse; Respiratory Function Tests; Walking | 2010 |
Serum biomarkers and clinical outcomes in heart failure patients treated de novo with carvedilol.
Topics: Adrenergic beta-Antagonists; Aged; Biomarkers; C-Reactive Protein; Carbazoles; Carvedilol; Endothelin-1; Female; Heart Failure; Humans; Inflammation Mediators; Interleukin-6; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Poland; Propanolamines; Stroke Volume; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha; Ventricular Function, Left | 2013 |
Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Calcium Channel Blockers; Carbazoles; Carvedilol; Cross-Over Studies; Delayed-Action Preparations; Diltiazem; Exercise Tolerance; Female; Humans; Male; Metoprolol; Natriuretic Peptide, Brain; Oxygen Consumption; Peptide Fragments; Propanolamines; Prospective Studies; Verapamil | 2014 |
Evaluation of beta-blockers on left ventricular dyssynchrony and reverse remodeling in idiopathic dilated cardiomyopathy: A randomized trial of carvedilol and metoprolol.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Biomarkers; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Double-Blind Method; Female; Humans; Male; Metoprolol; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Propanolamines; Prospective Studies; Recovery of Function; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2014 |
The effect of carvedilol on B-type natriuretic peptide and cardiac function in patients with heart failure and persistent atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Biomarkers; Carbazoles; Carvedilol; Case-Control Studies; Digoxin; Double-Blind Method; Female; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Propanolamines; Treatment Outcome; Ventricular Function, Left | 2015 |
Effect of Carvedilol on Serum Heart-type Fatty Acid-binding Protein, Brain Natriuretic Peptide, and Cardiac Function in Patients With Chronic Heart Failure.
Topics: Adrenergic beta-Antagonists; Age Factors; Biomarkers; Carbazoles; Carvedilol; Child; Child, Preschool; China; Chronic Disease; Echocardiography; Enzyme-Linked Immunosorbent Assay; Fatty Acid Binding Protein 3; Fatty Acid-Binding Proteins; Female; Heart Failure; Humans; Infant; Male; Myocardial Contraction; Natriuretic Peptide, Brain; Predictive Value of Tests; Propanolamines; Severity of Illness Index; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2015 |
High Dose β-Blocker Therapy Triggers Additional Reverse Remodeling in Patients With Idiopathic Non-Ischemic Cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Carbazoles; Cardiomyopathies; Carvedilol; Dose-Response Relationship, Drug; Female; Heart Rate; Humans; Japan; Male; Middle Aged; Natriuretic Peptide, Brain; Propanolamines; Stroke Volume; Ventricular Function, Left; Ventricular Remodeling | 2016 |
Anemia Is Associated With Blunted Response to β-Blocker Therapy Using Carvedilol - Insights From Japanese Chronic Heart Failure (J-CHF) Study.
Topics: Adrenergic beta-Antagonists; Aged; Anemia; Carvedilol; Chronic Disease; Female; Follow-Up Studies; Heart Failure; Hemoglobins; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Predictive Value of Tests; Stroke Volume | 2018 |
Carvedilol and Cardiac Biomarkers in Dialysis Patients: Secondary Analysis of a Randomized Controlled Trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Biomarkers; Carbazoles; Carvedilol; Female; Heart Diseases; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Propanolamines; Renal Insufficiency, Chronic; Troponin T | 2017 |
Assessment of clinical effect and treatment quality of immediate-release carvedilol-IR versus SLOW release carvedilol-SR in Heart Failure patients (SLOW-HF): study protocol for a randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Biomarkers; Carvedilol; Clinical Trials, Phase IV as Topic; Delayed-Action Preparations; Drug Compounding; Female; Heart Failure; Humans; Male; Multicenter Studies as Topic; Natriuretic Peptide, Brain; Peptide Fragments; Prospective Studies; Randomized Controlled Trials as Topic; Recovery of Function; Republic of Korea; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left | 2018 |
Tolerability, Efficacy, and Safety of Bisoprolol vs. Carvedilol in Japanese Patients With Heart Failure and Reduced Ejection Fraction - The CIBIS-J Trial.
Topics: Adult; Aged; Aged, 80 and over; Bisoprolol; Carvedilol; Heart Failure; Heart Rate; Humans; Japan; Middle Aged; Natriuretic Peptide, Brain; Stroke Volume; Treatment Outcome | 2019 |
Carvedilol Does Not Improve Exercise Performance in Fontan Patients: Results of a Crossover Trial.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Carvedilol; Child; Cross-Over Studies; Double-Blind Method; Exercise; Exercise Test; Female; Fontan Procedure; Heart Failure; Heart Rate; Humans; Male; Natriuretic Peptide, Brain; Oxygen Consumption; Peptide Fragments; Treatment Outcome; Young Adult | 2021 |
Clinical Characteristics and Outcome of Immediate-Release Versus SLOW-Release Carvedilol in Heart Failure Patient (SLOW-HF): a Prospective Randomized, Open-Label, Multicenter Study.
Topics: Biomarkers; Carvedilol; Heart Failure; Humans; Natriuretic Peptide, Brain; Peptide Fragments; Prospective Studies; Quality of Life; Stroke Volume | 2023 |
42 other study(ies) available for carvedilol and natriuretic peptide, brain
| Article | Year |
|---|---|
Improvement in left ventricular function in response to carvedilol is accompanied by attenuation of neurohumoral activation in patients with dilated cardiomyopathy.
Topics: 3-Iodobenzylguanidine; Adrenergic beta-Antagonists; Adult; Aged; Atrial Natriuretic Factor; Biomarkers; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Female; Heart Ventricles; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Norepinephrine; Propanolamines; Radiopharmaceuticals; Recovery of Function; Retrospective Studies; Stroke Volume; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Ventricular Function, Left | 2000 |
Carvedilol enhances atrial and brain natriuretic peptide mRNA expression and release in rat heart.
Topics: Adrenergic beta-Antagonists; Animals; Antioxidants; Atrial Natriuretic Factor; Carbazoles; Carvedilol; Guanylate Cyclase; Male; Myocardium; Natriuretic Peptide, Brain; Propanolamines; Rats; Rats, Inbred Lew; Receptors, Atrial Natriuretic Factor; RNA, Messenger | 2000 |
Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during beta-blocker therapy: a potential of hormone-guided treatment.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Echocardiography; Electrocardiography; Female; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Norepinephrine; Propanolamines; ROC Curve; Ventricular Function, Left | 2001 |
Myocardial contractile reserve under low doses of dobutamine and improvement of left ventricular ejection fraction with treatment by carvedilol.
Topics: Adrenergic beta-Antagonists; Biomarkers; Carbazoles; Carvedilol; Echocardiography; Echocardiography, Stress; Exercise Test; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Contraction; Natriuretic Peptide, Brain; Predictive Value of Tests; Propanolamines; Prospective Studies; Statistics as Topic; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left | 2002 |
Bedside B-type natriuretic peptide and functional capacity in chronic heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Biomarkers; Carbazoles; Carvedilol; Chronic Disease; Diuretics; Dose-Response Relationship, Drug; Follow-Up Studies; France; Furosemide; Heart Failure; Humans; Incidence; Lisinopril; Middle Aged; Natriuretic Peptide, Brain; Propanolamines; Severity of Illness Index; Spironolactone; Stroke Volume; Treatment Outcome | 2003 |
[The changes of plasma levels of brain natriuretic peptides in evaluation of treatment responses in chronic heart failure].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atrial Natriuretic Factor; Carbazoles; Carvedilol; Female; Heart Failure; Humans; Immunoradiometric Assay; Male; Metoprolol; Middle Aged; Natriuretic Peptide, Brain; Propanolamines; Radioimmunoassay | 2003 |
Brain natriuretic peptide response is heterogeneous during beta-blocker therapy for congestive heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Biomarkers; Blood Pressure; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Failure; Humans; Male; Metoprolol; Middle Aged; Myocardial Contraction; Natriuretic Peptide, Brain; Propanolamines; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left | 2004 |
Dismantling mandates in the treatment of heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Heart Failure; Heart Rate; Humans; Natriuretic Peptide, Brain; Nerve Tissue Proteins; Peptide Fragments; Propanolamines; Stroke Volume; Ventricular Function, Left | 2004 |
[Prediction of intolerance to beta blocker therapy in chronic heart failure patients using BNP].
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Female; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Predictive Value of Tests; Propanolamines; Risk Factors | 2004 |
Carvedilol modulates the expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in a rat model of volume-overload heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Blotting, Western; Carbazoles; Carvedilol; Echocardiography; Heart Failure; Hypoxia-Inducible Factor 1, alpha Subunit; Myocardium; Natriuretic Peptide, Brain; Polymerase Chain Reaction; Propanolamines; Rats; Rats, Sprague-Dawley; Reverse Transcription; RNA, Messenger; Transcription Factors; Up-Regulation; Vascular Endothelial Growth Factor A; Ventricular Function, Left | 2005 |
Dilated cardiomyopathy relieved as a result of beta-blocker therapy: a case report--key points in assessment of prognosis based on MIBG myocardial scintigraphy and BNP levels.
Topics: 3-Iodobenzylguanidine; Adrenergic beta-Antagonists; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Follow-Up Studies; Humans; Middle Aged; Natriuretic Peptide, Brain; Prognosis; Propanolamines; Radiopharmaceuticals; Severity of Illness Index; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2005 |
[Long-term outcome and tolerability of carvedilol therapy in Japanese patients with chronic heart failure].
Topics: Adrenergic beta-Antagonists; Asian People; Carbazoles; Carvedilol; Drug Tolerance; Female; Follow-Up Studies; Heart Failure; Heart Rate; Humans; Japan; Male; Middle Aged; Natriuretic Peptide, Brain; Prognosis; Propanolamines; Survival Rate; Treatment Outcome | 2006 |
COMPARE: comparison of the effects of carvedilol CR and carvedilol IR on left ventricular ejection fraction in patients with heart failure.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chemistry, Pharmaceutical; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Heart Failure; Humans; Natriuretic Peptide, Brain; Propanolamines; Randomized Controlled Trials as Topic; Research Design; Stroke Volume | 2006 |
The effect of beta-blocker (carvedilol) therapy on N-terminal pro-brain natriuretic peptide levels and echocardiographic findings in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Biomarkers; Carbazoles; Carvedilol; Drug Therapy, Combination; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Propanolamines; Stroke Volume; Ventricular Function, Left | 2007 |
Decline of plasma brain natriuretic peptide level after carvedilol therapy to treat dilated cardiomyopathy presenting with mechanical alternans.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Electrocardiography; Follow-Up Studies; Humans; Male; Myocardial Contraction; Natriuretic Peptide, Brain; Propanolamines; Ventricular Pressure | 2007 |
ACE-inhibitors, beta-blockers or the combination in heart failure: is it just an A-B-C ? : editorial to: effects of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure by Rosenberg et al.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Carbazoles; Carvedilol; Chronic Disease; Drug Therapy, Combination; Enalapril; Heart Failure, Systolic; Humans; Natriuretic Peptide, Brain; Peptide Fragments; Propanolamines; Risk Assessment; Time Factors; Treatment Outcome | 2008 |
Changing beta-blockers in heart failure: when is a class not a class?
Topics: Adrenergic beta-Antagonists; Atenolol; Bisoprolol; Carbazoles; Carvedilol; Heart; Heart Failure; Humans; Natriuretic Peptide, Brain; Propanolamines | 2008 |
Which factors predict the recovery of natural heart function after insertion of a left ventricular assist system?
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Female; Heart; Heart-Assist Devices; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Predictive Value of Tests; Propanolamines; Recovery of Function; Retrospective Studies; Time Factors; Ventricular Dysfunction, Left | 2008 |
Restrictive left ventricular filling pattern and its effect on the clinical course of systolic heart failure in patients receiving carvedilol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Blood Flow Velocity; Carbazoles; Carvedilol; Case-Control Studies; Echocardiography, Doppler; Exercise Tolerance; Female; Heart Failure, Systolic; Humans; Linear Models; Male; Middle Aged; Mitral Valve Stenosis; Natriuretic Peptide, Brain; Probability; Propanolamines; Reference Values; Risk Assessment; Severity of Illness Index; Stroke Volume; Survival Analysis; Treatment Outcome; Ventricular Dysfunction, Left | 2008 |
Effect of carvedilol on plasma adiponectin concentration in patients with chronic heart failure.
Topics: Adiponectin; Adrenergic beta-Antagonists; Biomarkers; Carbazoles; Carvedilol; Chronic Disease; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Natriuretic Peptide, Brain; Propanolamines; Severity of Illness Index; Stroke Volume; Tumor Necrosis Factor-alpha | 2009 |
Acute myocardial infarction after Kawasaki disease in an infant: treatment with coronary artery bypass grafting.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Coronary Aneurysm; Coronary Angiography; Coronary Artery Bypass; Coronary Stenosis; Heart Failure; Humans; Infant; Male; Mucocutaneous Lymph Node Syndrome; Myocardial Infarction; Natriuretic Peptide, Brain; Propanolamines; Stroke Volume; Ventricular Pressure | 2009 |
[B-type natriuretic peptide (BNP) levels and the effects of carvedilol on BNP levels in juvenile rats with right heart failure].
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Heart Failure; Natriuretic Peptide, Brain; Propanolamines; Random Allocation; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2009 |
Carvedilol may alleviate late cardiac remodelling following surgical ventricular restoration.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Cardiac Catheterization; Carvedilol; Drug Evaluation, Preclinical; Fibrosis; Gene Expression Regulation; Heart Ventricles; Hemodynamics; Male; Myocardial Infarction; Myocardium; Myocytes, Cardiac; Natriuretic Peptide, Brain; Organ Size; Postoperative Care; Propanolamines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Transforming Growth Factor beta1; Ventricular Remodeling | 2010 |
Dose-dependent prognostic effect of carvedilol in patients with chronic heart failure--special reference to transcardiac [corrected] gradient of norepinephrine.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Biomarkers; Carbazoles; Carvedilol; Chi-Square Distribution; Chronic Disease; Dose-Response Relationship, Drug; Female; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Natriuretic Peptide, Brain; Norepinephrine; Peptide Fragments; Propanolamines; Proportional Hazards Models; Risk Assessment; Risk Factors; Sympathetic Nervous System; Time Factors; Treatment Outcome | 2009 |
Decrease in plasma brain natriuretic peptide level in the early phase after the start of carvedilol therapy is a novel predictor of long-term outcome in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Biomarkers; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Failure, Systolic; Humans; Immunoradiometric Assay; Japan; Male; Middle Aged; Natriuretic Peptide, Brain; Propanolamines; Retrospective Studies; Stroke Volume; Survival Rate; Time Factors; Treatment Outcome | 2009 |
Combined amiodarone and low-dose carvedilol treatment for severe heart failure in childhood.
Topics: Adolescent; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Furosemide; Heart Failure; Hemodynamics; Humans; Natriuretic Peptide, Brain; Propanolamines; Recurrence; Spironolactone; Vasodilator Agents; Ventricular Dysfunction, Left | 2010 |
Comparative effects of carvedilol vs bisoprolol for severe congestive heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atrial Fibrillation; Bisoprolol; Carbazoles; Carvedilol; Disease-Free Survival; Drug Evaluation; Female; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Propanolamines; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
BNP levels predict outcome in pediatric heart failure patients: post hoc analysis of the Pediatric Carvedilol Trial.
Topics: Adrenergic beta-Antagonists; Age Factors; Biomarkers; Carbazoles; Cardiomyopathies; Carvedilol; Chi-Square Distribution; Child; Child, Preschool; Female; Heart Defects, Congenital; Heart Failure; Humans; Infant; Male; Multicenter Studies as Topic; Natriuretic Peptide, Brain; Predictive Value of Tests; Prognosis; Propanolamines; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Factors; Sensitivity and Specificity; Statistics, Nonparametric; Treatment Outcome | 2010 |
Letter by Lowenthal et al regarding article, "BNP levels predict outcome in pediatric heart failure patients: post hoc analysis of the Pediatric Carvedilol Trial".
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Child; Child, Preschool; Clinical Trials as Topic; Heart Defects, Congenital; Heart Failure; Humans; Natriuretic Peptide, Brain; Propanolamines | 2010 |
Usefulness of carvedilol in the treatment of chronic aortic valve regurgitation.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Animals; Aortic Valve Insufficiency; Atrial Natriuretic Factor; Bradycardia; Capillaries; Carbazoles; Carvedilol; Chronic Disease; Disease Models, Animal; Extracellular Matrix Proteins; Follistatin-Related Proteins; Gene Expression Regulation; Heart Rate; Hypertrophy, Left Ventricular; Male; Natriuretic Peptide, Brain; Propanolamines; Rats; Rats, Wistar; Receptors, Adrenergic; RNA, Messenger; Stroke Volume; Time Factors; Ultrasonography; Ventricular Function, Left; Ventricular Pressure | 2011 |
Cardiac AA amyloidosis in a patient with rheumatoid arthritis and systemic sclerosis: the therapeutic potential of biological reagents.
Topics: Aged; Amyloidosis; Antibodies, Antinuclear; Antirheumatic Agents; Arthritis, Rheumatoid; Benzimidazoles; Biphenyl Compounds; Carbazoles; Carvedilol; Drug Therapy, Combination; Dyspnea; Etanercept; Female; Furosemide; Glucocorticoids; Hand; Heart Failure; Humans; Immunoglobulin G; Lung Diseases, Interstitial; Natriuretic Peptide, Brain; Propanolamines; Radiography; Receptors, Tumor Necrosis Factor; Rheumatoid Factor; Ribonucleosides; Scleroderma, Systemic; Spironolactone; Sulfasalazine; Tetrazoles; Treatment Outcome | 2011 |
Urinary 8-hydroxy-2'-deoxyguanosine as a novel biomarker for predicting cardiac events and evaluating the effectiveness of carvedilol treatment in patients with chronic systolic heart failure.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adrenergic beta-Antagonists; Adult; Aged; Biomarkers; Carbazoles; Carvedilol; Chronic Disease; Death, Sudden, Cardiac; Deoxyguanosine; Female; Follow-Up Studies; Heart Failure, Systolic; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Predictive Value of Tests; Propanolamines; Prospective Studies; Risk Factors; Treatment Outcome | 2012 |
Increased low-grade inflammation is associated with lack of functional response to carvedilol in patients with systolic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Cohort Studies; Cytokines; Echocardiography; Female; Heart Failure, Systolic; Humans; Inflammation; Insulin Resistance; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Propanolamines; Quality of Life; Severity of Illness Index; Stroke Volume; Treatment Outcome | 2013 |
Clinical status and outcome of Japanese heart failure patients with reduced or preserved ejection fraction treated with carvedilol.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Monitoring; Female; Heart Failure; Humans; Japan; Male; Medication Therapy Management; Middle Aged; Natriuretic Peptide, Brain; Pharmacovigilance; Prognosis; Propanolamines; Proportional Hazards Models; Risk Factors; Severity of Illness Index; Sex Factors; Stroke Volume; Time; Treatment Outcome | 2013 |
Short-term follow-up of exercise training program and beta-blocker treatment on quality of life in dogs with naturally acquired chronic mitral valve disease.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Animals; Carbazoles; Carvedilol; Dogs; Echocardiography, Doppler; Female; Follow-Up Studies; Heart Rate; Lactic Acid; Male; Mitral Valve Insufficiency; Natriuretic Peptide, Brain; Peptide Fragments; Physical Conditioning, Animal; Propanolamines; Prospective Studies; Quality of Life; Statistics, Nonparametric | 2015 |
Left ventricular reverse remodeling with infantile dilated cardiomyopathy and pitfalls of carvedilol therapy.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Dose-Response Relationship, Drug; Female; Heart Failure; Humans; Infant; Male; Natriuretic Peptide, Brain; Prognosis; Propanolamines; Retrospective Studies; Time Factors; Ventricular Remodeling | 2016 |
Renal Denervation Attenuates Multi-Organ Fibrosis and Improves Vascular Remodeling in Rats with Transverse Aortic Constriction Induced Cardiomyopathy.
Topics: Alanine Transaminase; Angiotensin II; Animals; Aorta; Blood Pressure; Carbazoles; Cardiomegaly; Cardiomyopathies; Carvedilol; Constriction; Cystatin C; Denervation; Fibrosis; Heart Rate; Kidney; Malondialdehyde; Natriuretic Peptide, Brain; Organ Specificity; Oxidative Stress; Peptide Fragments; Procollagen; Propanolamines; Rats, Sprague-Dawley; Superoxide Dismutase; Transforming Growth Factor beta1; Vascular Remodeling | 2016 |
The expression of transforming growth factor-β1 in myocardial tissue and concentration of serum B-type natriuretic peptide in myocardial remodeling of Sprague-Dawley rats treated with carvedilol.
Topics: Animals; Carbazoles; Carvedilol; Immunohistochemistry; Male; Myocardium; Natriuretic Peptide, Brain; Propanolamines; Rats; Rats, Sprague-Dawley; Transforming Growth Factor beta1; Ventricular Remodeling | 2017 |
Left ventricular outflow tract pressure gradient changes after carvedilol-disopyramide cotherapy in a cat with hypertrophic obstructive cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Animals; Cardiomyopathy, Hypertrophic; Carvedilol; Cat Diseases; Cats; Disopyramide; Echocardiography; Male; Natriuretic Peptide, Brain; Peptide Fragments; Ventricular Outflow Obstruction; Voltage-Gated Sodium Channel Blockers | 2020 |
MitraClip or Ventricular Assist Device?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiac Resynchronization Therapy; Carvedilol; Clinical Decision-Making; Disease Progression; Enalapril; Female; Heart Failure; Heart-Assist Devices; Hospitalization; Humans; Middle Aged; Mineralocorticoid Receptor Antagonists; Mitral Valve Annuloplasty; Mitral Valve Insufficiency; Natriuretic Peptide, Brain; Oxygen Consumption; Patient Selection; Pulmonary Wedge Pressure; Recurrence; Severity of Illness Index; Spironolactone; Treatment Outcome | 2020 |
Performance of a cardiac lipid panel compared to four prognostic scores in chronic heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Biomarkers; Bisoprolol; Carvedilol; Cluster Analysis; Female; Heart Disease Risk Factors; Heart Failure; Humans; Lipidomics; Male; Multicenter Studies as Topic; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Proof of Concept Study; Randomized Controlled Trials as Topic; Regression Analysis; Survival Analysis; Treatment Outcome | 2021 |
Recurrent biventricular takotsubo cardiomyopathy with fatal outcome.
Topics: Atorvastatin; Carvedilol; Fatal Outcome; Female; Humans; Lisinopril; Natriuretic Peptide, Brain; Stroke Volume; Takotsubo Cardiomyopathy; Troponin I; Ventricular Function, Left | 2022 |